JournalThe plant
What kanna is
A succulent from the Cape, a family of alkaloids and a long record of use. The plant, before the product.
By the THRYVE team4 min read

A succulent from the Cape
Kanna is Sceletium tortuosum, also named Mesembryanthemum tortuosum: a short-lived perennial succulent herb with a creeping habit, in the family Aizoaceae.1 It grows wild in the karroid regions of South Africa's Western and Northern Cape.1
The plant has more than one name, and each records who was naming it. Kanna is its Nama name.2 Kougoed is Afrikaans, from kou, to chew, and goed, stuff.1 Sceletium is its name in English.1
Wild kanna is under pressure. A review update in 2008 reported that wild stands had been severely diminished by over-harvesting, poor veld management and possibly plant diseases.3 Selected plant material has been cultivated on a small commercial scale.1
How it has been used
San hunter-gatherers and Khoi pastoralists used kanna for millennia before European explorers and settlers wrote about it: against thirst, hunger and fatigue, as a medicine, and for social and spiritual purposes.34
The usual way was to chew it.5 It has also been smoked, made into a tea and prepared as a tincture.526 One traditional preparation crushed the plant, sealed it in a bag and left it in the hot sun for eight days before it was dried.16
The written record starts in the 1600s.1 The first documented reports, by Van Riebeeck in about 1660, describe kanna as an item of Khoi trade.1 Governor Simon van der Stel's expedition to Namaqualand painted the plant in 1685, and its journal recorded that the Nama gathered it in October and called it Canna.14 The heritage page sets out that record in order, with a source for each date.
What is in it
The compounds researchers study in kanna are alkaloids.5 Twenty-five have been identified, in four structural classes, and the mesembrine class is the main one.5 Three of the main ones are mesembrine, mesembrenone and mesembrenol.78
How much of them a plant carries is not fixed. In the plant, total alkaloid content varies from 0.05% to 2.3% of dry weight.1 With a spread like that, the percentage on a label is the line to read first.
One older question has a published answer. In 1996, a review that reassembled 300 years of written records found no evidence that kanna or its alkaloids are hallucinogenic.6
In laboratory assays, a kanna extract blocked the serotonin transporter and inhibited the enzyme PDE4.*7 The extract was Zembrin, a branded one, and the assays involved no people.7 What that finding means, and what it does not, is the subject of the next article.
What one gummy carries
THRYVE has one active, printed on the front of the pouch and again in the Supplement Facts: Kanna Extract at 5% alkaloids, 30 mg in each gummy. A pouch of 10 gummies holds 300 mg of extract.9
We do not turn that percentage into milligrams of alkaloids yet. How the supplier measures it, and which alkaloids it counts, is a question we have put to them, and a figure we cannot check is a figure we do not print.
Every batch is tested by a third party, and the back of the pouch carries a QR code printed with the words SCAN FOR LAB RESULTS.9 The label states the dose; the lab report for the batch is one scan away.
How it is sold, and where
Kanna extracts are sold today as ingredients in dietary supplements and functional foods.8 In the United States, kanna is not listed in the federal controlled-substance schedules (21 CFR 1308.11 to 1308.15, checked against the eCFR of 2026-11-18).10
That is the federal position. State rules are a question for counsel, and this page will carry their answer when we have it in writing.
What the research has, and has not, tested
Every human study cited on these pages was placebo-controlled, small (60 people or fewer), short (one dose to 3 months) and in healthy adults.5111213214 Of the five, four used one branded extract, Zembrin, and the fifth does not name its extract.111213214 In 2010, South Africa's first bioprospecting permit for kanna allowed one company to produce and export Zembrin.15
None tested a THRYVE gummy, so we report them as what research found about kanna's alkaloids, never as what a THRYVE gummy does.9
That is the plant, before the product. The label line by line is on the ingredients page; the dose and the warning are in the last article of this journal.
Who should not take it
The pouch is specific about this, and we quote it in full.
ADULTS 21+
WARNING: Effects vary by individual.
Do not use if you take an SSRI, SNRI, MAOI, tricyclic antidepressant, triptan, or any other medication that affects serotonin.
Consult a physician before use if you take any prescription medication, have a medical condition, or are pregnant or nursing.
Keep out of reach of children.
A review published in 2021 found no reports to date of severe adverse reactions or herb-drug interactions, and still advises caution with medication of the kind the second warning line names; it also flags medicines that act on the enzyme PDE4.1
* Marks a statement about what kanna or its alkaloids did in published research, or how a historical writer described it. None of it is a claim about this product.
[?]These statements made have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
Numbered in the order each source is first cited on this page. Titles are printed as their publishers printed them.
- Brendler T, Brinckmann JA, Feiter U, Gericke N, Lang L, Pozharitskaya ON, Shikov AN, Smith M, Van Wyk BE (2021). Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems. Current Neuropharmacology 19(9):1384-1400. doi:10.2174/1570159X19666210215124737 Back to the text
- Dimpfel W, Gericke N, Suliman S, Chiegoua Dipah GN (2016). Psychophysiological Effects of Zembrin® Using Quantitative EEG Source Density in Combination with Eye-Tracking in 60 Healthy Subjects. A Double-Blind, Randomized, Placebo-Controlled, 3-Armed Study with Parallel Design. Neuroscience and Medicine (Scientific Research Publishing) 7(3):114-132. doi:10.4236/nm.2016.73013 Back to the text
- Gericke N, Viljoen AM (2008). Sceletium--a review update. Journal of Ethnopharmacology 119(3):653-663. doi:10.1016/j.jep.2008.07.043 Back to the text
- Manganyi MC, Bezuidenhout CC, Regnier T, Ateba CN (2021). A Chewable Cure "Kanna": Biological and Pharmaceutical Properties of Sceletium tortuosum. Molecules 26(9):2557. doi:10.3390/molecules26092557 Back to the text
- Olatunji TL, Siebert F, Adetunji AE, Harvey BH, Gericke J, Hamman JH, Van der Kooy F (2022). Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. Journal of Ethnopharmacology 287:114711. doi:10.1016/j.jep.2021.114711 Back to the text
- Smith MT, Crouch NR, Gericke N, Hirst M (1996). Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Journal of Ethnopharmacology 50(3):119-130. doi:10.1016/0378-8741(95)01342-3 Back to the text
- Harvey AL, Young LC, Viljoen AM, Gericke NP (2011). Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology 137(3):1124-1129. doi:10.1016/j.jep.2011.07.035 Back to the text
- Murbach TS, Hirka G, Szakonyiné IP, Gericke N, Endres JR (2014). A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin®) in rats. Food and Chemical Toxicology 74:190-199. doi:10.1016/j.fct.2014.09.017 Back to the text
- THRYVE (client) (2026). THRYVE kanna gummies pouch: front, Supplement Facts, directions, warning. Back to the text
- Drug Enforcement Administration (U.S. Department of Justice) (2026). 21 CFR Part 1308 - Schedules of Controlled Substances, §§1308.11-1308.15 (Schedules I-V). Electronic Code of Federal Regulations (eCFR), up to date as of 2026-11-18 21 CFR 1308.11-1308.15. www.ecfr.gov/current/title-21/chapter-II/part-1308 Back to the text
- Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van Honk J (2013). Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology 38(13):2708-2716. doi:10.1038/npp.2013.183 Back to the text
- Nell H, Siebert M, Chellan P, Gericke N (2013). A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. Journal of Alternative and Complementary Medicine 19(11):898-904. doi:10.1089/acm.2012.0185 Back to the text
- Chiu S, Gericke N, Farina-Woodbury M, Badmaev V, Raheb H, Terpstra K, Antongiorgi J, Bureau Y, Cernovsky Z, Hou J, Sanchez V, Williams M, Copen J, Husni M, Goble L (2014). Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. Evidence-Based Complementary and Alternative Medicine 2014:682014. doi:10.1155/2014/682014 Back to the text
- Hoffman JR, Markus I, Dubnov-Raz G, Gepner Y (2020). Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women. Journal of Strength and Conditioning Research 34(9):2476-2481. doi:10.1519/JSC.0000000000003693 Back to the text
- SAnews (South African Government News Agency) (2010). 10 000 San to benefit from bio-prospecting license. SAnews, Government of South Africa (4 October 2010). www.sanews.gov.za/node/7216 Back to the text